

## ASX ANNOUNCEMENT

### Appendix 4C – Quarterly Cash Flow Report – Clarification Announcement.

**7<sup>th</sup> August 2020:** Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® system and the Enhanced Infusion System technologies, updates the released of Appendix 4C - Quarterly Cashflow report for the period ending 30<sup>th</sup> June 2020 lodged on the 31<sup>st</sup> July 2020.

The Company at the 30<sup>th</sup> June 2020 had drawn down \$75k of the unsecured revolving working capital facility for up to \$1 million from Halonna Pty Ltd, an entity associated with the Chairman, Dr Michael Monsour (**Facility**).

Interest is payable at a commercial unsecured overdraft rate, presently 8.51%, quarterly in arrears. The Facility must be repaid in full on the earliest of 30 June 2021, completion of an equity raising of more than \$250,000 and 14 days after a change of control event<sup>1</sup> occurs in relation to the Company.

Aggregate payments to related parties and their associates amounted to \$31k for the quarter. These payments were for executive salary of the CFO Ross Mangelsdorf, who is also a director.

Costs have been reviewed and tightened to ensure progress with development and to prepare when our partners are able to finalise negotiations. Directors have agreed to defer payment of directors' fees to assist preservation of cash.

Authorised for release by the Board.

For more information, please contact: [investorrelations@analyticamedical.com](mailto:investorrelations@analyticamedical.com)

For more information about the PeriCoach System, visit: [www.PeriCoach.com](http://www.PeriCoach.com)

For more information about Analytica, visit [www.AnalyticaMedical.com](http://www.AnalyticaMedical.com)

#### About Analytica Limited


Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or

---

<sup>1</sup> A change of control occurs if (a) any person, whether alone together with the person's associates (other than the Halonna and its associates), acquires a relevant interest in 20% or more of the issued share capital of Analytica or (b) a person (either alone or with that person's associates) who was unable to control the composition of Analytica's Board as at the date of this document, acquires that ability.





satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance for urinary incontinence in Australia and has CE mark and USFDA 510(k) clearance.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.